 |
|
Treatment Considerations While Awaiting the Ideal Bullous Pemphigoid Trial
Arch Dermatol. 2002;138:404.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THE SEARCH for an effective and safe therapy for bullous pemphigoid
(BP) is important. Compared with other cutaneous disorders, BP has a relatively
high morbidity and may occasionally be fatal. It most frequently affects the
elderly, who are especially susceptible to the adverse effects of systemic
drugs such as corticosteroids. The first-line agents that are used by most
dermatologists are systemic corticosteroids. In mild cases of BP, there is
a tendency to use potent topical steroids or anti-inflammatory agents other
than corticosteroids, such as oral antibiotics, nicotinamide, or dapsone.
In rare instances, nonsteroidal immunosuppressive therapy is instituted.
Khumalo et al1 review BP treatments in
this issue of the ARCHIVES. In their literature review, they identify, outline,
discuss, and critique effectively 6 randomized controlled trials comprising
293 patients. None of the trials used a placebo group. In the first study,
there was no difference in the effectiveness of methylprednisolone compared
with . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
A Systematic Review of Treatments for Bullous Pemphigoid
Nonhlanhla P. Khumalo, Dedeé F. Murrell, Fenella Wojnarowska, and Gudula Kirtschig
Arch Dermatol. 2002;138(3):385-389.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study
Joly et al.
Arch Dermatol 2005;141:691-698.
ABSTRACT
| FULL TEXT
|
